BIG PIcture
BIG PIcture
Biosimilars save
the U.S. healthcare
system an estimated
$5.4 billion each year*.
Biocon Biologics is a proud leader in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialization of the highest quality biosimilars in the world.
Biocon Biologics
A fully integrated global biosimilars company, all in on biosimilars.
- A unique biosimilars portfolio spanning insulins, recombinant proteins, and monoclonal antibodies
- Cutting-edge science and research capabilities
- Experience built from a successful global partnership with Mylan/Viatris
- Global-scale manufacturing with high standards of quality and compliance
20+
biosimilars approved or in development
10
biosimilars launched across global markets
120+
countries where biosimilars are available
5.8+M
served globally by Biocon Biologics’ biosimilars
* Estimates of reductions in direct spending on biologic drugs from 2014 through 2024.Reference: Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
Legacy Of Success
A long-standing presence in the biosimilars industry
Biocon Biologics has emerged as a leader in biosimilars in the U.S. and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been making for years.
Successfully integrates acquired businesses globally, establishing direct commercial presence in U.S.
Biocon Biologics acquires Viatris' global biosimilars business to become a fully integrated biosimilars company in the U.S.
Solidifies foothold in the U.S. and global biosimilars space
Continues partnership with Viatris after Mylan/Upjohn merger
Launches world's first trastuzumab biosimilar
Partners with U.S.-based Mylan to co-develop biosimilar antibodies portfolio for global markets
First and only company to commercialize a Pichia pastoris derived rh-insulin rh=recombinant human
Evolves into bio-pharmaceuticals
Founded to improve access to quality bioenzymes
Successfully integrates
acquired businesses
globally, establishing
direct commercial
presence in U.S.
Biocon Biologics acquires Viatris' global biosimilars business to become a fully integrated biosimilars company in the U.S.
Solidifies foothold in the U.S. and global biosimilars space
Continues partnership with Viatris after Mylan/Upjohn merger
Launches world's first trastuzumab biosimilar
Partners with U.S.-based Mylan to co-develop biosimilar antibodies portfolio for global markets
First and only company to commercialize a Pichia pastoris derived rh-insulin rh=recombinant human
Evolves into
bio-pharmaceuticals
Founded to improve access to quality bioenzymes
PORTFOLIO
Path-breaking
offerings with a focus
on the future.
With a unique portfolio of monoclonal antibodies, recombinant proteins and insulins, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access, investing more than $1 billion in R&D and global-scale manufacturing over the last 2 decades.
FULPHILA
(pegfilgrastim-jmdb)
injection*†
FIRST to receive
U.S. approval – 2018
†Click here for Full Prescribing Information.
OGIVRI
(trastuzumab-dkst)
injection†‡
FIRST to receive
U.S. approval – 2017
†Click here for Full Prescribing Information,including BOXED WARNING.
JOBEVNE
(bevacizumab-nwgd)†‡
U.S. approval – 2025
†Click here for Full Prescribing Information.
Filed in U.S., Canada and the EU
Pertuzumab‡
In global clinical trials
Etanercept§
Approved in the EU in 2020
YESINTEK
(ustekinumab-kfce) †
U.S. approval – 2024
†Click here for Full Prescribing Information.
SEMGLEE
(insulin glargine-yfgn)
injection
FIRST U.S. approval
of interchangeable
biosimilar – 2021
†Click here for Full Prescribing Information.
Glargine 300U
In early development/
preclinical stage
KIRSTY
(insulin aspart-xjhz)
injection
FIRST US approval
of interchangeable biosimilar – 2025
Recombinant
human insulin*
Approved in
40+ global markets
YESAFILI
(aflibercept-jbvf)
FIRST U.S. approval of interchangeable biosimilar – 2024†
†Not yet launched in the U.S.
7 assets
In early development/
preclinical stage
Biocon Biologics: an integrated player with proven end-to-end expertise
Research and
innovation
Product
Development
Clinical
Trials
Global-scale
Manufacturing
Regulatory
Sciences
Commercialization
Portfolio
Oncology
Immunology
Diabetes
Bone Health
Ophthalmology
Our ongoing efforts continue to expand affordable
access to biosimilars for patients worldwide
#Biocon Biologics has acquired the Viatris global rights to partnered asset.
EU=European Union; U.S.=United States.
